TB-500
TB-500 after the April 15 FDA reclassification — the research base, safety signals, expected compounded pricing, and the BPC-157 combination question.
Last reviewed
Quick Summary
What it is. A synthetic fragment of the naturally occurring protein Thymosin Beta-4 (Tβ4) — most commonly the 17-amino-acid active region.
Most-studied uses. Tissue repair, wound healing, muscle recovery, cardiovascular remodeling (primarily animal models and equine veterinary use).
Current U.S. legal status (April 2026). Removed from FDA Category 2 on April 15, 2026. Pending final 503A Bulks List placement at the July 23–24, 2026 PCAC meeting. Legal via prescription through a licensed compounding pharmacy.
Expected post-PCAC price. $120–$250 per 5mg vial. Combination BPC-157/TB-500 formulations: $180–$300.
Evidence base. Significant preclinical and veterinary literature. Human clinical trial data sparse. Commonly used alongside BPC-157.
What is TB-500?
TB-500 is the common name for a synthetic version of a specific active fragment of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein present in essentially every cell of the human body. Tβ4 plays a role in cell migration, tissue repair, and actin sequestration.
The synthetic TB-500 sold by compounders is a shorter, typically 17-amino-acid fragment believed to capture much of the parent molecule’s tissue-repair activity with improved practical handling characteristics. It is not identical to pharmaceutical-grade Tβ4 (which has been studied in clinical trials for dry eye disease and epidermolysis bullosa), and the two should not be conflated.
What the Research Shows
Preclinical and veterinary evidence
TB-500 — and Tβ4 more broadly — has been studied extensively in rodent and porcine wound-healing models (accelerated cutaneous wound closure and improved tissue organization), cardiac injury models (cardioprotection following ischemic insult, with improved left ventricular function), corneal injury models (faster epithelial regeneration — this line of research is what led to pharmaceutical development of Tβ4 for dry eye disease), muscle and tendon injury models (accelerated recovery and improved functional outcomes), and equine veterinary medicine (TB-500 has been used extensively in racehorse soft-tissue injury recovery, with well-developed veterinary protocols).
Human clinical data
Human clinical trials of the parent compound Thymosin Beta-4 have been conducted for specific indications (dry eye, certain wound-healing contexts). Human clinical trial data on the TB-500 fragment specifically — as compounded and sold in the peptide market — is much more limited.
Practitioner experience with TB-500 for soft-tissue injury is substantial, often in combination with BPC-157. The practitioner-reported outcomes are generally favorable, with the same caveat that applies to the rest of this category: practitioner experience is a real signal, but it is not a substitute for controlled human trial data.
The BPC-157 + TB-500 Combination Question
No conversation about TB-500 avoids the combination question. Practitioners routinely prescribe BPC-157 and TB-500 together for soft-tissue indications, and compounding pharmacies frequently offer pre-mixed combination vials.
The rationale: The two peptides are thought to act through complementary mechanisms. BPC-157 is proposed to act more locally at the tissue-level healing cascade (angiogenesis, nitric oxide signaling). TB-500 is proposed to act more systemically on cellular migration, actin dynamics, and repair signaling. The combination is theorized to produce a more comprehensive repair response than either alone.
The evidence: Practitioner-reported experience with the combination is favorable. Rigorous human comparative trials (BPC-157 alone vs TB-500 alone vs combination) are effectively absent.
Our honest take: If your prescriber recommends the combination, it is a reasonable clinical judgment supported by mechanistic rationale and practitioner consensus — not a marketing gimmick. If your prescriber recommends only one, that is also defensible. What you should be skeptical of is a compounding pharmacy pushing the combination aggressively without a prescriber relationship, because that pattern often reflects margin incentive rather than clinical reasoning.
Legal and Regulatory Status
April 15, 2026 reclassification
TB-500 was among the 12 peptides removed from FDA Category 2 on April 15, 2026. Licensed compounding pharmacies may now prepare it under valid prescription.
July PCAC outlook
Industry expectation is that TB-500 will receive clean approval at the July PCAC meeting, likely without significant restrictions. The peptide’s connection to the well-characterized parent compound Thymosin Beta-4 strengthens its regulatory profile.
Anti-doping status
TB-500 is on the World Anti-Doping Agency prohibited list under the growth factor / repair-peptide category. WADA-affiliated athletes at any level should not use TB-500. This is independent of the April 15 reclassification — federal reclassification does not affect sport-governing-body rules.
State-level variance
Same state-level considerations apply as with other reclassified peptides. See the state-by-state tracker for your jurisdiction.
How It’s Typically Administered
Informational only; dosing is prescriber-determined.
TB-500 is most commonly administered by subcutaneous or intramuscular injection. Oral and topical routes are rare; IV is restricted to specialty clinical settings.
Typical practitioner-prescribed courses for soft-tissue indications last 4–6 weeks, with some extension to 8 weeks for more significant injuries. Continuous long-duration use is not the standard protocol.
Reported Safety Signals
Short-term adverse events reported in practitioner use are typically mild — local injection-site reactions, transient fatigue on initial administration, and rare reports of mild flu-like symptoms in the first week.
The theoretical angiogenesis concern that applies to BPC-157 in the context of occult malignancy applies equally or more to TB-500, given Tβ4’s more substantial role in vascular biology. Experienced prescribers screen for active or recent cancer history before prescribing.
Long-term human safety data is limited.
Expected Pricing (Post-PCAC)
| Format | Expected price range |
|---|---|
| 5mg vial (lyophilized) | $120–$250 |
| 10mg vial | $200–$400 |
| Combination BPC-157/TB-500 (5mg/5mg) | $180–$300 |
How to Source It Legitimately
Same framework as BPC-157: prescriber → compounding pharmacy → COA-verified batch → cold-chain shipping → supervision. Apply the 10-point pharmacy checklist every time.
Common Questions
TB-500 vs Thymosin Beta-4 — are they the same thing?
Not exactly. Thymosin Beta-4 is the full 43-amino-acid parent protein. TB-500 is a synthetic fragment (typically 17 amino acids) of that parent, designed to capture the tissue-repair active region. Pharmaceutical-grade Tβ4 studied in clinical trials is distinct from compounded TB-500 available through the compounding pharmacy channel.
Can I use TB-500 without BPC-157?
Yes, in principle. Whether you should is a clinical decision for your prescriber. For some indications, TB-500 monotherapy is the reasonable choice. For many soft-tissue injuries, the combination is more commonly prescribed.
Is TB-500 legal in 2026?
Post-April 15, 2026, TB-500 is legally compoundable by licensed pharmacies under valid prescription. The gray-market “research chemical” channel remains outside the law regardless of federal reclassification. See the FDA timeline.
Does TB-500 show up on drug tests?
TB-500 is on the WADA prohibited list and can be detected by specialized sports anti-doping testing. Standard employment drug screens do not typically include TB-500, but WADA-affiliated athletes should assume detection risk.
How long does TB-500 take to work?
Practitioner reports describe onset over 2–4 weeks for soft-tissue indications, with meaningful effect emerging over 4–8 weeks.
What are the side effects of TB-500?
Reported side effects are typically mild — injection-site reactions, transient fatigue. Serious adverse events are rare in practitioner reports. Long-term human data is limited.
Is TB-500 worth the price over BPC-157 alone?
This is a prescriber call. For indications where TB-500’s systemic cell-migration mechanism is clinically relevant, the added cost may be justified. For simpler tissue-specific indications, BPC-157 alone may be sufficient. Neither is universally superior.
Related Compounds
- BPC-157 — Most commonly paired with TB-500 for soft-tissue indications. ������������������
Educational content, not medical advice. Decisions about peptide use belong between you and a licensed clinician. © 2026 PeptidesBeat.